These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 7553955)
1. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells]. Guo Y; Xing Z Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955 [TBL] [Abstract][Full Text] [Related]
2. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells. Guo YS; Xing ZL Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727 [TBL] [Abstract][Full Text] [Related]
3. Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients. Chen YM; Yang WK; Ting CC; Tsai WY; Yang DM; Whang-Peng J; Perng RP Chest; 1997 Oct; 112(4):960-6. PubMed ID: 9377959 [TBL] [Abstract][Full Text] [Related]
4. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion]. Mao G; Gao Z; Wang Q Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956 [TBL] [Abstract][Full Text] [Related]
5. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion. Takahashi K; Sone S; Kimura S; Ogura T; Monden Y Chest; 1993 Jun; 103(6):1732-8. PubMed ID: 8404092 [TBL] [Abstract][Full Text] [Related]
6. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3. Strauss G; Gückel B; Wallwiener D; Moldenhauer G Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216 [TBL] [Abstract][Full Text] [Related]
7. [Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)]. Han B; Jia Y; Zhou M Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):91-3, 128. PubMed ID: 7553959 [TBL] [Abstract][Full Text] [Related]
8. [An experimental study of the antitumor activity of tumor-infiltrating lymphocytes (TIL) in human tongue carcinoma in vitro]. Guo W Zhonghua Kou Qiang Yi Xue Za Zhi; 1992 Sep; 27(5):259-61, 318. PubMed ID: 1306434 [TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion]. Liu X Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867 [TBL] [Abstract][Full Text] [Related]
10. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)]. Xu ZY Zhonghua Zhong Liu Za Zhi; 1990 Sep; 12(5):345-7. PubMed ID: 2177396 [TBL] [Abstract][Full Text] [Related]
11. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2]. Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896 [TBL] [Abstract][Full Text] [Related]
12. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion]. Li DJ Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114 [TBL] [Abstract][Full Text] [Related]
13. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491 [TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of various LAK cells against autologous lung cancer, K-562 and Daudi cells. Kimura H; Yamaguchi Y Jpn J Clin Oncol; 1989 Sep; 19(3):222-8. PubMed ID: 2810822 [TBL] [Abstract][Full Text] [Related]
15. A new approach to the treatment of malignant effusion. Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253 [TBL] [Abstract][Full Text] [Related]
16. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies. Kimoto Y Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321 [TBL] [Abstract][Full Text] [Related]
17. Soluble HLA class I molecules in malignant pleural and peritoneal effusions and its possible role on NK and LAK cytotoxicity. Amirghofran Z; Sheikhi AK; Kumar PV; Saberi Firouzi M J Cancer Res Clin Oncol; 2002 Aug; 128(8):443-8. PubMed ID: 12200601 [TBL] [Abstract][Full Text] [Related]
18. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma]. Li D; Zhang X; Song Y Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811 [TBL] [Abstract][Full Text] [Related]
19. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Schendel DJ; Gansbacher B Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731 [TBL] [Abstract][Full Text] [Related]
20. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432. Uchida A; Micksche M J Natl Cancer Inst; 1983 Oct; 71(4):673-80. PubMed ID: 6413742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]